‘ BJUI Clinical Dilemma’: Recurrent high‐grade non‐muscle‐invasive bladder cancer in 2026

Documenti analoghi

• Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer
  di: Jacob I. Taylor, et al.
  Pubblicazione: (2024)
• Response to comment on ‘Drug‐releasing intravesical floating technology for sequential gemcitabine and docetaxel in non‐muscle‐invasive bladder cancer’
  di: Melinda Z. Fu, et al.
  Pubblicazione: (2026)
• Drug‐releasing intravesical floating technology for sequential gemcitabine and docetaxel in non‐muscle‐invasive bladder cancer
  di: Ashley C. Rhodes, et al.
  Pubblicazione: (2025)
• Prognostic role of the neutrophil/lymphocyte ratio in high‐risk BCG‐naïve non‐muscle‐invasive bladder cancer treated with intravesical gemcitabine/docetaxel
  di: Mohamad Abou Chakra, et al.
  Pubblicazione: (2024)
• Improving the pathway to correct treatment for patients with muscle‐invasive bladder cancer: exploring the myths around the BladderPath trial
  di: Richard T. Bryan, et al.
  Pubblicazione: (2025)